Thanks. Question about competition

Thanks. Question about competition


I'm Synaphai on ihub and SA but for some reason couldn't get that username to work here.

Revenue after approval will be crucial so Nader really needs to get the price right.

I'd be very interested in thoughts about how cabotegravir approval, which should also be early next year, will affect leronlimab adoption. It's a once a month IM injection with rilpivirine to replace standard of care HIV therapy. In two trials of cabotegravir plus rilpivirine injections with 591 participants total, patient satisfaction was very high, 94 and 91 percent, so it doesn't present significantly worse safety issues and a once a month injection, even if it is IM and at a healthcare facility, should be very attractive to patients. Plus it has Glaxosmithkline behind it so it will be marketed well.

It will run the risk of eventually developing resistance. I'm unclear on whether the cabotegravir plus rilpivirine will be on option for patients with current multidrug resistance.